Tevogen announces $9-11 billion valuation for COVID-19 T cell therapy

WARREN, N.J. - Tevogen Bio Holdings Inc. (NASDAQ:TVGN), currently valued at $170.43 million and showing a remarkable 105.89% return over the past year according to InvestingPro, announced Monday a risk-adjusted net present value estimate of $9 billion to $11 billion for its lead product TVGN-489, an allogeneic precision T cell therapy for COVID-19.

The therapy is being developed to treat SARS-CoV-2 infection in high-risk vulnerable patients and for Long-COVID in patients with persistent viral reservoirs. Trading at $0.93 per share, the company’s stock tends to move independently of broader market trends, with a beta of -0.76.

According to the company’s statement, Phase I clinical trial results published in Blood Advances showed promising outcomes. High-risk ambulatory patients, half of whom were immunocompromised, received a single infusion of TVGN-489 across four escalating dose levels.

The company reported no dose-limiting toxicities, infusion reactions, cytokine release syndrome, or graft-versus-host disease in the trial. Patients in the treatment arm demonstrated faster symptom improvement compared to the observational arm.

Nasal PCR testing showed at least 88% viral elimination by Day 4 in 92% of patients, and more than 99% elimination in all patients by Day 14. No disease progression, recurrent COVID-19, or cases of Long-COVID were observed during six months of follow-up.

Neal Flomenberg, Chief Scientific Officer of Tevogen Bio, noted that two cancer patients were able to proceed to stem cell transplant shortly after receiving TVGN-489, without experiencing COVID-19 reactivation.

The valuation reflects U.S. revenue potential only and does not include the value of the company’s broader ExacTcell platform technology.

The company stated it plans to provide additional valuation updates on its internally developed assets, including its product pipeline. While InvestingPro analysis indicates the stock is currently overvalued, analysts maintain a $10 price target, suggesting significant upside potential. Get access to more exclusive financial insights and 8 additional ProTips for TVGN with InvestingPro.

In other recent news, Tevogen Bio Holdings Inc. announced a projected cumulative 5-year top-line revenue of approximately $3.5 billion for its pipeline product TVGN 930, targeting non-solid tumor malignancies linked to the Epstein-Barr Virus. The company estimates the risk-adjusted Net Present Value for this product exceeds $250 million in the U.S. market alone. Tevogen also highlighted the need for SARS-CoV-2 treatments for immunocompromised individuals, emphasizing its investigational treatment, TVGN 489, which targets the entire viral genome. Additionally, the company reported a 60% rise in institutional ownership of its common stock in the first quarter of 2025, with Vanguard and BlackRock significantly increasing their holdings. Tevogen expects to receive $1 million in grant funding from KRHP LLC to advance its AI-powered drug discovery platform, Tevogen.AI, as part of a larger $10 million non-dilutive funding agreement. Furthermore, the company disclosed that its executive officers and board members own over 74% of its outstanding common stock, ensuring substantial insider control over its strategic direction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.